Scarica l'app Stockscreener
0.55
9.01%
-0.047
Dopo l'orario di chiusura:
.54
-0.01
-1.82%
Precedente Chiudi:
$0.597
Aprire:
$0.5957
Volume 24 ore:
918.13K
Relative Volume:
0.21
Capitalizzazione di mercato:
$2.93M
Reddito:
-
Utile/perdita netta:
$-11.38M
Rapporto P/E:
-0.0198
EPS:
-27.73
Flusso di cassa netto:
$-12.72M
1 W Prestazione:
-22.38%
1M Prestazione:
-34.40%
6M Prestazione:
+50.89%
1 anno Prestazione:
-83.58%
Intervallo 1D:
$0.54
$0.597
Intervallo di 1 settimana:
$0.5377
$0.6498
Portata 52W:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Nome
Windtree Therapeutics Inc
Settore
Industria
Telefono
(215) 488-9300
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Confronta WINT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.55 | 2.93M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.54 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-26 | Iniziato | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
Warrington’s Windtree Therapeutics Acquires Waste Management Company - MSN
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MyChesCo
Windtree Therapeutics (WINT) Publishes Promising Phase 2 Study R - GuruFocus
Ratios Revealed: Decoding Windtree Therapeutics Inc (WINT)’s Financial Health - DWinneX
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | WINT Stock News - GuruFocus
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study - Yahoo Finance
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May - Defense World
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Titan Environmental to be acquired by Windtree Therapeutics - Investing.com Nigeria
Titan Environmental to be acquired by Windtree Therapeutics By Investing.com - Investing.com South Africa
Windtree Therapeutics Stock Is Volatile This Week: What's Going On? - Benzinga
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics receives $7M offer for oncology platform By Investing.com - Investing.com South Africa
Warrington’s Windtree Therapeutics Acquires A Waste Management Company - BUCKSCO.Today
Windtree Therapeutics Raises $3.9M Through Note Agreements - TipRanks
Windtree Therapeutics (WINT) Receives Offer for Oncology Platfor - GuruFocus
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate - The Manila Times
Windtree Therapeutics (WINT) Receives Offer for Oncology Platform | WINT Stock News - GuruFocus
Windtree Therapeutics receives offer for preclinical oncology drug candidate - TipRanks
Windtree Therapeutics receives $7M offer for oncology platform - Investing.com Australia
Windtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in Royalties - Nasdaq
Windtree's $1.5 Billion Oncology Drug Deal Signals Major Strategic ShiftSee Full Terms - Stock Titan
Working to clean up its finances, Windtree Therapeutics gets into the garbage business - The Business Journals
Windtree to Acquire Titan Environmental Services; Shares Surge - marketscreener.com
Windtree Stock Is Rising Tuesday: What's Going On? - Benzinga
Windtree Therapeutics (WINT) to Acquire Titan Environmental Serv - GuruFocus
Windtree Announces Transformational Agreement To Acquire Revenue Generating Environmental Services Business - marketscreener.com
Windtree Therapeutics announces agreement to acquire Titan Environmental - TipRanks
Windtree Therapeutics (WINT) Acquires Titan Environmental Services to Enhance Profitability | WINT Stock News - GuruFocus
Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business - Yahoo Finance
Windtree Therapeutics Announces Move into Cryptocurrency Payments and Holdings - MSN
Windtree Announces Plan for Cryptocurrency Treasury Policy | WIN - GuruFocus
Windtree Therapeutics to accept cryptocurrency payments - Investing.com Australia
Windtree Therapeutics to accept cryptocurrency payments By Investing.com - Investing.com South Africa
Windtree Therapeutics announces plan for cryptocurrency treasury policy - TipRanks
Windtree Therapeutics (WINT) Embraces Cryptocurrency as Payment Option | WINT Stock News - GuruFocus
Windtree Therapeutics (WINT) to Accept Cryptocurrency Payments: A Strategic Shift Amid Financial Challenges - Coinfomania
Windtree Therapeutics Creates Cryptocurrency Treasury Plan - marketscreener.com
Windtree Therapeutics IncTo Create Cryptocurrency Policy For Payments And Assets - marketscreener.com
Major Biotech Company Windtree Embraces Crypto: Plans Bitcoin Payments and Digital Asset Treasury Strategy - Stock Titan
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 110.2% - Defense World
Windtree Therapeutics Targets July for Interim Data from Key Cardiogenic Shock Study - MSN
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference - MSN
Windtree Therapeutics (WINT) Targets Key Study Analysis for July 2025 | WINT Stock News - GuruFocus
Windtree says interim results for SEISMiC SCAI Stage C study set for July 2025 - TipRanks
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - marketscreener.com
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 | WINT Stock News - GuruFocus
Windtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025 - Nasdaq
Critical Phase 2 Data Coming for Istaroxime in Severe Cardiogenic Shock Treatment - Stock Titan
Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.32%
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):